Promising Schizophrenia Drug, Cobenfy, Will Likely Face Access Challenges
Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...
Is the FDA contributing to the homelessness crisis?
The FDA’s REMS program has been found to have unintentionally created barriers to accessing clozapine, a crucial ...
STAT3d
Despite setback, AbbVie’s big bet on neuroscience has yet to play out
For AbbVie, the failure of a high-profile schizophrenia drug hardly marks its last chance to invest in neuroscience. But the ...
Too Old to Operate15h
FDA Approves Cobenfy for Adults With Schizophrenia
The U.S. Food and Drug Administration has approved Cobenfy (xanomeline and trospium chloride), a first-in-class muscarinic ...